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Background: Sepsis is a common and severe complication in premature neonates, particularly those born with low birth weights
(<2500 g). Neonatal sepsis is steadily emerging as a leading cause of neonatal mortality in Pakistan. Lactoferrin is a natural
product with broad-spectrum antimicrobial properties and glycoprotein that is actively involved in innate immune host responses.
Clinical trials have revealed its protective effect on sepsis, but lactoferrin dosage, duration, and role in the prevention of sepsis
are still uncertain.
Objective: We aimed to establish the efficacy of bovine lactoferrin in the prevention of late-onset sepsis and to determine the
optimal dose and method of administering bovine lactoferrin that may contribute to improvement in overall survival of low birth
weight infants.
Methods: We will implement the study in 2 phases at the Aga Khan University Hospital. The first phase, which we have
completed, was formative research. This phase mainly focused on a qualitative exploration of perceptions about feeding and
caring practices of low birth weight newborns and a trial of improved practices for the preparation and administration of bovine
lactoferrin to newborns. The second phase is a 3-arm double-blind randomized controlled trial. In this phase, we randomly
allocated 2 different daily oral prophylactic doses of bovine lactoferrin (150 mg or 300 mg) and placebo to 300 low–birth weight
neonates starting within the first 72 hours of birth and continuing for the first 28 days of life.
Results: The study protocol was approved by the Ethics Review Committee of Aga Khan University on August 16, 2017. Data
collection began in April 2018 and was completed in September 2020. Data analyses are yet to be completed. We expect the
results to be published in peer-reviewed journals by autumn of 2021.
Conclusions: This intervention, if effective, has the potential to be translated into a safe, affordable, and widely utilized treatment
to prevent sepsis and, subsequently, may improve the survival outcomes of low birth weight neonates in Pakistan and other low-
and middle-income countries.
Trial Registration: ClinicalTrials.gov NCT03431558; https://clinicaltrials.gov/ct2/show/NCT03431558
International Registered Report Identifier (IRRID): PRR1-10.2196/23994
(JMIR Res Protoc 2021;10(3):e23994) doi: 10.2196/23994
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Introduction
Globally, 15.5% of newborns are born with low birth weight,
with 96.5% of these births occurring in low-income countries
[1]. Approximately 4 million babies in their neonatal period die
each year [2]. An estimated 1 million of these deaths occur due
to infectious causes, including sepsis, pneumonia, and
meningitis, and 60% to 80% of all neonatal deaths are
low-birth-weight newborns [1,3]. According to 2018 data, the
neonatal mortality rate in Pakistan is 42 per 1000 live births [4].
The current rate of reduction in neonatal mortality is insufficient
to achieve United Nations Sustainable Development Goal 3 of
reducing neonatal mortality to less than 12 per 1000 live births
by 2030 [5].
The incidence of sepsis in neonates is inversely proportional to
gestational age and birth weight [6]. Late-onset sepsis is sepsis
arising after the perinatal period (>72 hours following birth),
which occurs due to microorganisms acquired during the
delivery or hospital stay [6,7]. In Pakistan, sepsis caused by
multidrug-resistant organisms is common and challenging to
treat, resulting in sepsis-related mortality [8]. Late detection,
poor sensitivity of diagnostic tests, and nonspecific clinical
features further delay the recognition of neonatal sepsis.
Furthermore, detection and treatment may not always prevent
the high costs of prolonged hospital stays in neonatal intensive
care units and late or impaired neurodevelopment. Multiple
interventions have been introduced to prevent the morbidity
and mortality associated with such serious infections. It is well
established that breast milk has beneficial effects against
neonatal sepsis in vulnerable populations [9]. This protection
is due to the multiple anti-infective, anti-inflammatory, and
immunoregulatory factors transmitted through milk. These
include secretory antibodies, glycans, lactoferrin, leukocytes,
cytokines, and other components produced by the mother’s
immune system [9].
Lactoferrin is a whey protein in mammalian milk. It has a
multifunctional role in host defense via a myriad of antimicrobial
and anti-inflammatory functions. The concentration of
lactoferrin is highest in colostrum, decreasing as milk matures,
and the decrease is slower in the milk of mothers of preterm
infants [10]. Bovine lactoferrin shares similar bioactivity and
homology (77%) with its isoform, human lactoferrin, and
exhibits even higher in vitro antimicrobial activity than that
exhibited by human lactoferrin [11]. A pilot study [12] in the
United States found a protective effect of bovine
lactoferrin–enhanced formula (containing 850 mg bovine
lactoferrin/L) against lower respiratory tract illnesses in infants
compared to that of regular formula. A recent review [13]
concluded that lactoferrin was a safe intervention, and its most
likely future use in children would be to protect against enteric
infections and neonatal sepsis. Furthermore, it concluded that
bovine lactoferrin had the potential in to reduce sepsis in
low-birth-weight infants and aid in the reduction of child
mortality [13]. A randomized clinical trial [14] in India to
evaluate the efficacy of bovine lactoferrin in preventing
late-onset sepsis in low-birth-weight neonates reported a
significant reduction in the incidence of late-onset sepsis in the
bovine lactoferrin supplementation group compared to the
placebo.
Despite promising experimental data, clinical information on
bovine lactoferrin in infants is scarce, with minimal data from
low- and middle-income countries [14]. We sought to address
the gaps in the current literature regarding the optimal dose,
administration method, and efficacy of bovine lactoferrin in
decreasing the incidences of late-onset sepsis and necrotizing
enterocolitis in low-birth-weight infants in Pakistan. We also
aim to determine the role of bovine lactoferrin supplementation
in improving neonatal survival.
The primary objective of this study is to evaluate bovine
lactoferrin efficacy in reducing the incidence of late-onset sepsis
and to define the optimal daily dose and administration method
of bovine lactoferrin to prevent late-onset neonatal sepsis in
low-birth-weight and preterm neonates. The secondary objective
of this study is to evaluate the effectiveness of bovine lactoferrin
in reducing the incidence of necrotizing enterocolitis in
low-birth-weight and preterm neonates, and the effectiveness
of bovine lactoferrin in improving neonatal survival during the
first 28 days of life.
Methods
Study Design
This study consists of 2 phases. The first phase was a qualitative
component with formative research and a trial of improved
practices. The second phase was a 3-arm double-blind
individually randomized controlled trial.
In the first phase, we conducted formative research before the
initiation of the clinical trial to explore the acceptability of the
delivery of the intervention. We used qualitative research
methods, such as in-depth interviews, focus group discussions,
and direct observations at the household level, to ascertain the
practices and perceptions around feeding and care of
low-birth-weight newborns. Based on the information from
themes related to adherence, feasibility, and acceptability of
bovine lactoferrin use, we carried out an additional trial of
improved practices of preparation and administering of bovine
lactoferrin to the low-birth-weight newborn by the caregivers
at home.
In the second phase, we conducted a 3-arm randomized
controlled trial to compare 2 different prophylactic oral doses
of bovine lactoferrin (150 mg or 300 mg) and placebo, given
daily over the first 28 days of life. We initiated the treatment
within the first 72 hours following birth.
Study Setting
This study was conducted at the Aga Khan University Hospital
in Karachi, Pakistan, in collaboration with researchers from the
School of Public Health, the University of Sydney, Australia.
The Aga Khan University Hospital is a state-of-the-art Joint
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Commission International accredited tertiary care hospital and
has 2 postnatal wards with a fully equipped 24-bed neonatal
intensive care unit with an extensive clinical support unit.
Annually, approximately 5500 deliveries take place with a
known prevalence of 15% to 18% for low-birth-weight neonates.
The hospital also has a clinical trial unit, laboratory, and
pharmacy, along with other essential hospital services to conduct
clinical trials.
Study Population and Eligibility Criteria
For the formative research, we recruited women, their husbands,
and mothers or mothers-in-law from Aga Khan University
Hospital, and the qualitative researcher made an appointment
to interview them at the hospital using a standard structured
questionnaire. The trial participants, parents with
low-birth-weight neonates (birth weight <2500 g and ≥ 1000
g) in each treatment group, were recruited from the Aga Khan
University Hospital. All low-birth-weight neonates with
gestational age from 28 weeks to 36 weeks 5 days, with no sign
of sepsis, and on oral feeding within 72 hours of birth were
eligible. We obtained written informed consent from parents or
caregivers after assurance that the family planned to stay in the
study area for at least 1 month.
Exclusion criteria were neonates with congenital anomalies,
culture-proven early-onset sepsis, history of severe maternal
chorioamnionitis, or group B streptococcus colonization during
pregnancy, gestational age less than 27 weeks 6 days, birth
weight less than 1000 g, and parental refusal to consent.
Sample Size
Phase 1: Formative Research
Following the inclusion criteria, 10-15 low-birth-weight
neonates’ parents or caregivers were recruited purposively for
the trial of improved practices. We conducted 30 in-depth
interviews.
Phase 2: Clinical Trial
A total of 100 low-birth-weight neonates were enrolled in each
group, leading to an aggregate of 300 neonates. We estimate
that the sample size with a 2-sided α of 5%, power of 80%, and
10% lost to follow up. Based on current hospital data, the
incidence of neonatal sepsis in the placebo group is 25%. We
conducted 30 in-depth interviews with parents and caregivers
of low-birth-weight infants. We enrolled 15 low-birth-weight
infants for trial of improved practices. Based on these
assumptions, the required sample size in each trial arm was
calculated as 95 low-birth-weight neonates (rounded to 100
low-birth-weight neonates), leading to a total of 300
low-birth-weight neonates.
Randomization, Allocation, and Masking
An independent statistician from the University of Sydney
produced a computer-generated random allocation sequence
using Stata (version 15; StataCorp LLC) software with a 1:1:1
ratio for the 3 arms of the trial (an allocation probability of
one-third per treatment arm) and a block size of 9 for
approximately anticipated number of newborns recruited each
day.
Once an infant met the eligibility criteria, we provided an
information sheet to the parents, in English and the local
language, explaining (1) the benefits of lactoferrin as a
nutritional supplement along with the method of administration
and (2) the placebo and its ingredients. Informed consent was
obtained from the parents, after which we enrolled the neonates
in the study. We blinded the participants and study teams to the
group allocation. We delivered the treatment kits to the study
site before initiation of the study.
Intervention
We will evaluate 2 different strengths (150 mg and 300 mg) of
bovine lactoferrin as the intervention treatment. The color of
bovine lactoferrin powder in each intervention and placebo
(D–Glucose) are identical in appearance. The study staff
administered the first oral dose of the trial supplement to the
neonate at the hospital in the presence of the mother or the
caregiver on the third day of life with a single daily dose mixed
with milk (preferentially breast milk otherwise formula milk)
and the mother or caregiver continued to administer the
supplement/placebo for 28 days. We stored the supplement
sachets at room temperature and maintained an inventory at the
clinical trial unit at the Aga Khan University Hospital. We
monitored adherence by weekly collection of used empty sachets
from the parents before providing them with the next set of
sachets for the subsequent week.
Retention and Follow-up
We followed the newborns weekly (for 28 ± 2 days) for general
well-being, recognition of danger signs, and adherence to
supplementation. Daily follow-ups were completed during the
hospital stay until discharge. At the time of discharge, we
provided the participants with 1 week’s supply of supplements.
A telephone follow-up was conducted midweek, and a home
visit was conducted once a week. The study investigators
conducted the first follow-up visit after discharge from the
neonatal care unit.
Data Collection and Management
The research team captured data electronically using tablets
equipped with special-purpose programs. We ran a pilot before
the implementation of the trial to avoid technical errors. The
tablets transferred the captured data to a secured database on
the server at Aga Khan University with a secure copy at the
University of Sydney.
At each follow-up visit, at home or at the hospital, a
questionnaire was administered about the history of illnesses
and feeding practices during the previous week. The criteria for
identifying a baby with presumed clinical sepsis included any
signs or symptoms such as lethargy, apnea, tachypnea,
respiratory distress, reluctance to feed, temperature instability,
feed intolerance, vomiting, aspirates, abdominal distention, and
seizures. We define sepsis as a baby with any of the criteria of
presumed sepsis in addition to either increased C-reactive
protein level (>1 mg/dL) or an increased or decreased white
blood cell count (7.0-23.0×103/uL), hypoglycemia (<40 mg/dL),
or positive blood culture.
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We conducted a complete physical examination on every visit.
In addition, anthropometric measurements were taken at birth,
on day 14, and on day 28. If any of the above symptoms were
found or there was clinical suspicion of sepsis in a neonate, we
performed a workup (sepsis screen) according to the standard
protocol of the hospital, which includes complete blood count,
C-reactive protein level, blood culture, and admission.
Statistical Analysis
We will use SPSS software (version 19.0; IBM Corp) for
statistical analysis. For continuous data, we will report the mean
and standard deviation or median and interquartile range. We
will report the baseline characteristics of the study population
with frequencies and percentages. To compare categorical
variables, we will use chi-square tests, and to compare
continuous variables, we will use paired t tests. To assess the
outcome variable, incident neonatal sepsis, we will use applied
logistic regression and report odds ratios and 95% confidence
intervals for all predictor variables. Initially, we will conduct
bivariate logistic regression analyses to estimate an unadjusted
odds ratio for each variable. We will examine the predictors
that demonstrate an association with the outcome (P value <.25)
in multiple logistic regression models. We will consider a P
value ≤.05 as significant.
Safety Reporting
Previously published evidence shows that orally administered
lactoferrin decreases sepsis and necrotizing enterocolitis in
preterm neonates without any adverse effects [15,16]; however,
if any adverse events occur, it will be reported in accordance
with local institutional ethics committee policies. We will define
an adverse event as any untoward medical occurrence in a trial
participant who has been administered the trial product and
which does not necessarily have a causal relationship with the
treatment.
Serious adverse events will be any untoward medical occurrence
that at any dose results in death, is life-threatening (ie, the infant
is at risk of death at the time of the event), requires inpatient
hospitalization or prolongation of existing hospitalization, or
other important medical events which, in the opinion of the
investigator, are likely to become serious if untreated.
A suspected unexpected serious adverse reaction will be defined
as an serious adverse event that is related to the drug or device
and is unexpected (ie, not listed in the investigator brochure or
approved Product Information and Informed Consent Form
[17]).
Ethical Approval and Consent to Participate
The Ethics Review Committee of the Aga Khan University
approved the study (ID 4873-Ped-ERC-17). The National
Bioethics Committee of Pakistan granted approval for the study
to be conducted on human participants. The study was also
approved by the Research Integrity & Ethics Administration,
Human Research Ethics Committee, The University of Sydney
(ID 2017/420).
Written informed consent was obtained from all study
participants prior to enrollment in the study. We will take special
care to ensure the confidentiality and privacy of the study
participants’ medical histories and personal information. We
will store all sources of information in a password-protected
predefined program, using tablets (at the time of enrollment and
subsequent follow-up visits) at the Data Management Unit (The
Aga Khan University). All source documents will be maintained
in locked files and will only be available to people directly
involved in the study.
Results
The study protocol was approved on August 16, 2017. Data
collection began in April 2018 and was completed in September
2020. Data analyses are yet to be completed. We expect the
results to be published in peer-reviewed journals by autumn
2021.
Discussion
This study will provide information on the effectiveness of
bovine lactoferrin in preventing late-onset neonatal sepsis in
low-birth-weight neonates and will be used to identify the
optimal dosage and administration method. Our study approach
aims to prevent neonatal infections; current treatment approaches
involve treating neonatal infections when they occur. The current
approach, which focuses on early detection of infections in
newborns through postnatal care and treatment with antibiotics,
runs the risk of worsening antimicrobial resistance, which is
already an emerging crisis. Our approach, through the use of
prophylactic bovine lactoferrin supplements, will be
cost-effective, greatly reduce the risk of microbial resistance to
antibiotics, and can be implemented in all settings through
various health care providers who would initiate the treatment.
A review [15] of clinical trials found that despite the small
sample size, the preliminary results of the trials showed a
positive effect of lactoferrin on the prevention of neonatal
infections. It also concluded that if proven to be effective,
lactoferrin can become a cost-effective intervention that can
potentially impact neonatal mortality and morbidity worldwide
[15]. In a 2017 Cochrane review [16], enteral lactoferrin was
found to reduce the rate of late-onset sepsis (risk ratio 0.59,
95% CI 0.40-0.87; P=.008; from 6 trials with 886 participants)
and the rate of necrotizing enterocolitis (risk ratio 0.40,
0.18-0.86; P=.02; from 4 trials with 750 participants) in preterm
neonates. The review [16] also concluded that although
lactoferrin holds great potential for late-onset sepsis and
necrotizing enterocolitis prevention, multiple questions still
need to be answered, including the administration method and
optimal dosage. Our study aims to address these gaps in the
current literature.
This intervention, if effective, has the potential to be translated
into a safe, affordable, and widely utilized intervention to
prevent sepsis and subsequently improve survival in
low-birth-weight neonates in Pakistan and other low-and
middle-income countries. Following the achievement of
conclusive results, we plan to scale up the intervention. Our
long-term vision is to produce lactoferrin within Pakistan as a
byproduct of the dairy industry, for use as part of the standard
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neonatal care package for the support of low-birth-weight babies,
delivered both in hospital and at home.
The results of this trial will be disseminated to the government,
academic, and policy-making communities, as well as to the
wider public in a peer-reviewed journal and at relevant national
and international conferences.
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